159 related articles for article (PubMed ID: 32282437)
21. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.
Iqbal J; Wu HX; Hu N; Zhou YH; Li L; Xiao F; Wang T; Jiang HL; Xu SN; Huang BL; Zhou HD
Obes Rev; 2022 Jun; 23(6):e13435. PubMed ID: 35194917
[TBL] [Abstract][Full Text] [Related]
22. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.
Pradhan R; Yin H; Yu O; Azoulay L
Diabetes Care; 2022 Apr; 45(4):819-829. PubMed ID: 35104330
[TBL] [Abstract][Full Text] [Related]
23. Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study.
Dong YH; Wu JH; Chang CH; Lin JW; Wu LC; Toh S
Pharmacotherapy; 2022 Jun; 42(6):483-494. PubMed ID: 35508702
[TBL] [Abstract][Full Text] [Related]
24. Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes.
Yen FS; Hou MC; Cheng-Chung Wei J; Shih YH; Hsu CY; Hsu CC; Hwu CM
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1255-1264.e18. PubMed ID: 37331413
[TBL] [Abstract][Full Text] [Related]
25. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.
Faillie JL; Yu OH; Yin H; Hillaire-Buys D; Barkun A; Azoulay L
JAMA Intern Med; 2016 Oct; 176(10):1474-1481. PubMed ID: 27478902
[TBL] [Abstract][Full Text] [Related]
26. Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.
Schechter M; Melzer Cohen C; Fishkin A; Rozenberg A; Yanuv I; Sehtman-Shachar DR; Chodick G; Clark A; Abrahamsen TJ; Lawson J; Karasik A; Mosenzon O
Cardiovasc Diabetol; 2023 May; 22(1):126. PubMed ID: 37244998
[TBL] [Abstract][Full Text] [Related]
27. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Curr Med Res Opin; 2018 Jun; 34(6):1125-1133. PubMed ID: 29557199
[TBL] [Abstract][Full Text] [Related]
28. Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonists for Kidney Transplant Recipients With Type 2 Diabetes.
Sato T; Azuma Y; Ozone C; Okazaki M; Takeda A; Okada M; Futamura K; Hiramitsu T; Goto N; Narumi S; Watarai Y
J Clin Endocrinol Metab; 2023 Sep; 108(10):2597-2603. PubMed ID: 36974363
[TBL] [Abstract][Full Text] [Related]
29. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
[TBL] [Abstract][Full Text] [Related]
30. Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes.
Pradhan R; Yin H; Yu OHY; Azoulay L
Diabetes Care; 2022 Oct; 45(10):2289-2298. PubMed ID: 35866685
[TBL] [Abstract][Full Text] [Related]
31. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
32. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260
[TBL] [Abstract][Full Text] [Related]
33. Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management.
Taha MB; Yahya T; Satish P; Laird R; Agatston AS; Cainzos-Achirica M; Patel KV; Nasir K
Curr Atheroscler Rep; 2022 Aug; 24(8):643-654. PubMed ID: 35624390
[TBL] [Abstract][Full Text] [Related]
34. Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients With Type 2 Diabetes.
Lu S; Yin H; Yu OHY; Azoulay L
Epidemiology; 2022 Jul; 33(4):563-571. PubMed ID: 35394977
[TBL] [Abstract][Full Text] [Related]
35. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials.
Tran S; Retnakaran R; Zinman B; Kramer CK
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():68-76. PubMed ID: 29364587
[TBL] [Abstract][Full Text] [Related]
37. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Dawwas GK; Smith SM; Park H
Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
[TBL] [Abstract][Full Text] [Related]
38. The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis.
Potts JE; Gray LJ; Brady EM; Khunti K; Davies MJ; Bodicoat DH
PLoS One; 2015; 10(6):e0126769. PubMed ID: 26121478
[TBL] [Abstract][Full Text] [Related]
39. Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery to GLP-1 receptor agonist treatment.
Stenberg E; Näslund E
Int J Obes (Lond); 2023 Apr; 47(4):251-256. PubMed ID: 36670155
[TBL] [Abstract][Full Text] [Related]
40. GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus.
Dahiya L; Kaur R; Kumar R; Kumar M; Palta K
Curr Diabetes Rev; 2020; 16(4):279-292. PubMed ID: 31057118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
